279 related articles for article (PubMed ID: 31113871)
1. As a downstream target of the AKT pathway, NPTX1 inhibits proliferation and promotes apoptosis in hepatocellular carcinoma.
Zhao Y; Yu Y; Zhao W; You S; Feng M; Xie C; Chi X; Zhang Y; Wang X
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113871
[TBL] [Abstract][Full Text] [Related]
2. microRNA-1914, which is regulated by lncRNA DUXAP10, inhibits cell proliferation by targeting the GPR39-mediated PI3K/AKT/mTOR pathway in HCC.
Sun L; Wang L; Chen T; Yao B; Wang Y; Li Q; Yang W; Liu Z
J Cell Mol Med; 2019 Dec; 23(12):8292-8304. PubMed ID: 31576658
[TBL] [Abstract][Full Text] [Related]
3. Carboxypeptidase A6 Promotes the Proliferation and Migration of Hepatocellular Carcinoma by Up-regulating AKT Signaling Pathway.
Huang QB; Zhang HW; Liao ZB
Curr Med Sci; 2019 Oct; 39(5):727-733. PubMed ID: 31612389
[TBL] [Abstract][Full Text] [Related]
4. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis.
Huang Y; Xiang B; Liu Y; Wang Y; Kan H
Cancer Lett; 2018 Nov; 437():56-66. PubMed ID: 30165194
[TBL] [Abstract][Full Text] [Related]
5. LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway.
Wang J; Luo Z; Yao T; Li W; Pu J
J Cell Physiol; 2019 May; 234(5):6908-6916. PubMed ID: 30317590
[TBL] [Abstract][Full Text] [Related]
6. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
[TBL] [Abstract][Full Text] [Related]
7. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
8. STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma.
Lan Y; Han J; Wang Y; Wang J; Yang G; Li K; Song R; Zheng T; Liang Y; Pan S; Liu X; Zhu M; Liu Y; Meng F; Mohsin M; Cui Y; Zhang B; Subash S; Liu L
Cell Death Dis; 2018 Feb; 9(2):236. PubMed ID: 29445189
[TBL] [Abstract][Full Text] [Related]
9. AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma.
Wang LL; Jin XH; Cai MY; Li HG; Chen JW; Wang FW; Wang CY; Hu WW; Liu F; Xie D
Cancer Lett; 2018 Feb; 414():71-80. PubMed ID: 29126912
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of AURKA and HSF1 suppresses proliferation and promotes apoptosis in hepatocellular carcinoma by activating endoplasmic reticulum stress.
Shen Z; Yin L; Zhou H; Ji X; Jiang C; Zhu X; He X
Cell Oncol (Dordr); 2021 Oct; 44(5):1035-1049. PubMed ID: 34176092
[TBL] [Abstract][Full Text] [Related]
11. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
[TBL] [Abstract][Full Text] [Related]
12. Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.
Wang C; Jin G; Jin H; Wang N; Luo Q; Zhang Y; Gao D; Jiang K; Gu D; Shen Q; Huo X; Hu F; Ge T; Zhao F; Chu W; Shu H; Yao M; Cong W; Qin W
Oncotarget; 2015 Feb; 6(5):2903-16. PubMed ID: 25609201
[TBL] [Abstract][Full Text] [Related]
13. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
14. Small nucleolar RNA ACA11 promotes proliferation, migration and invasion in hepatocellular carcinoma by targeting the PI3K/AKT signaling pathway.
Wu L; Zheng J; Chen P; Liu Q; Yuan Y
Biomed Pharmacother; 2017 Jun; 90():705-712. PubMed ID: 28419966
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.
Wu HT; Xie CR; Lv J; Qi HQ; Wang F; Zhang S; Fang QL; Wang FQ; Lu YY; Yin ZY
Lab Invest; 2018 Aug; 98(8):1014-1024. PubMed ID: 29785050
[TBL] [Abstract][Full Text] [Related]
16. NMI promotes hepatocellular carcinoma progression via BDKRB2 and MAPK/ERK pathway.
Zhao J; Dong QZ; Zhong F; Cai LL; Qin ZY; Liu Y; Lin CZ; Qin LX; He FC
Oncotarget; 2017 Feb; 8(7):12174-12185. PubMed ID: 28077802
[TBL] [Abstract][Full Text] [Related]
17. DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis.
Qu D; Cui F; Lu D; Yang Y; Xu Y
Cancer Sci; 2019 Jan; 110(1):157-165. PubMed ID: 30417471
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
[TBL] [Abstract][Full Text] [Related]
19. Hsa_circ_0070269 inhibits hepatocellular carcinoma progression through modulating miR-182/NPTX1 axis.
Su X; Su J; He H; Zhan Y; Liu H
Biomed Pharmacother; 2019 Dec; 120():109497. PubMed ID: 31606623
[TBL] [Abstract][Full Text] [Related]
20. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
